Search

Displaying results 4811 - 4820 of 7186 in total
  1. Drug

    Camptothecin

    go.drugbank.com/drugs/DB04690
    Investigational

    Camptothecin is an alkaloid isolated from the stem wood of the Chinese tree, <i>Camptotheca acuminata</i>. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I.

  2. Drug

    ALM201

    go.drugbank.com/drugs/DB17206
    Investigational

    ALM201 is an anti-angiogenic synthetic peptide identified from the endogenous human protein, FKBPL. It is being investigated in the treatment of various cancers.[A254556]

  3. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    Clinical development with previous fumagillin derivatives has been limited by their toxicity profile. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases

  4. Drug

    LNP-nCoVsaRNA Vaccine

    go.drugbank.com/drugs/DB15799
    Experimental

    LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. … As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine.

  5. Drug

    8-chlorotheophylline

    go.drugbank.com/drugs/DB14132
    Experimental

    The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous system. 8-chlorotheophylline produces … a number of effects including nervousness, restlessness, insomnia, headache, and nausea, which are primarily attributed to its ability to block the adenosine receptor [A33889, A1539].

  6. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.

  7. Drug

    Chamaecyparis obtusa leaf

    go.drugbank.com/drugs/DB14686
    Investigational

    Mixtures: Rhodd Ato Repair Body So Ap
  8. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  9. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  10. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.